[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-adult-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-adult-onset":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652918","obesial-a-prospective-interventional-real-world-study-of-a-multidisciplinary-obesity-management-programme-100652918",false,"NCT07779343","OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme","OBESIAL","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* BMI ≥30 kg\u002Fm²\n* Written informed consent obtained prior to enrolment\n\nExclusion Criteria:\n\n* Refusal to participate or inability to adhere to follow-up procedures\n* Pregnancy at enrolment\n* Severe or unstable comorbidities compromising safety or participation, including:\n\n  * Recent acute cardiovascular event (\\\u003C60 days)\n  * Active malignancy\n  * Severe unstable organic disease\n* Previous bariatric surgery\n* Obesity pharmacotherapy within the previous 90 days\n* Known contraindication to planned therapeutic options\n* Severe unstable psychiatric disorders\n* Genetic obesity or obesity secondary to uncontrolled endocrine disease\n\nExclusion Criteria During Follow-up\n\n* Pregnancy occurring during follow-up\n* Initiation of chronic treatment associated with weight gain","ALL","18 Years","65 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.",[27,28,29,30],"Obesity Difficult Airway Airway Management","Obesity Adult Onset","Obesity and Cardiovascular Risk","Obesity Type 2 Diabetes Mellitus",[32,33,34,35,36],"obesity","adult obesity","multidisciplinary care","lifestyle interventions","GLP-1 receptor agonists","RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-01-22",{"date":45,"type":21},"2028-01-23",{"name":47,"class":48},"University of Health Sciences, Algeria","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100644625","phase-2-a-randomized-double-blind-placebo-controlled-study-evaluating-the-effect-of-lae102-injection-in-combination-with-tirzepatide-on-body-in-obese-participants-100644625","NCT07671391","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the Informed Consent Form (ICF);\n2. Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF;\n3. BMI ranging from 28.0 to 40.0 kg\u002Fm2 during the screening;\n4. Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%;\n\nExclusion Criteria:\n\n1. A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes);\n2. Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL.\n\n   Obesity related:\n3. Diagnosed with secondary obesity;\n4. Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study;\n5. Uncontrolled thyroid disease, or screening criteria.","75 Years",{"count":59,"type":21},60,[61],"PHASE2","This study is a randomized, double-blind, placebo-controlled trial aimed at exploring the effects of LAE102 injection in combination with Tirzepatide on body composition.",[28],[65,28,66],"LAE102 injection","Investigator-initiated trial","NOT_YET_RECRUITING","2026-06-22",{"date":70,"type":41},"2026-06-26",{"date":72,"type":21},"2026-08",{"date":74,"type":21},"2027-12",{"name":76,"class":48},"Shanghai Zhongshan Hospital"]